Inactive Instrument

Intervacc AB Stock Nasdaq Stockholm

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

May. 22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
May. 15	Sweden's Intervacc Elects New Chair	MT

Analysts' recommendations: Intervacc AB

24-05-20	Penser reiterates motivated value for Intervacc - report met expectations	FW
24-02-21	Penser lowers Intervacc's motivated value	FW
23-11-17	Penser makes minor estimate adjustments in Intervacc	FW
23-05-04	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
23-02-20	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	2026-02-04
Jan Persson DFI	Director of Finance/CFO	-	2020-02-05
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	2020-06-10

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	2026-05-12
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	2023-12-31
Björn Ingemar Odlander BRD	Director/Board Member	68	2024-12-31

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Aug. 19 Earnings release - Q2 2026

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Market Cap	416M 42.63M 37.49M 34.83M 32.03M 60.07M 4.13B 61.15M 162M 2.01B 160M 157M 6.99B	P/E 2026 *	-5.55x	P/E 2027 *	-5.55x
Enterprise Value	323M 33.11M 29.12M 27.05M 24.88M 46.66M 3.21B 47.49M 126M 1.56B 124M 122M 5.43B	EV / Sales 2026 *	18.3x	EV / Sales 2027 *	11.8x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

May. 22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
May. 15	Sweden's Intervacc Elects New Chair	MT
May. 15	Appoints Emil Billbäck as chairman	RE
May. 13	Intervacc elects Emil Billbäck as chairperson of board	RE
May. 13	Intervacc AB Announces Board Changes	CI
May. 13	Intervacc Q1 net sales down at SEK 3.4 million	RE
May. 13	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 12	Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026	CI
Apr. 16	Intervacc: Strangvac vaccine approved in Iceland	RE
Apr. 16	Intervacc AB Announces Approval and Launch of Strangvac Vaccine in Iceland	CI
Mar. 19	Intervacc AB Publ Announces Breakthrough Protection Against Streptococcus Suis Infection in Piglets	CI
Mar. 17	Calendar Tuesday March 17	FW
Mar. 13	Calendar Monday March 16 - Friday March 20	FW

Jun. 04	Redeye initiates coverage of Intervacc	AQ
May. 22	Intervacc: Positive results	AQ
May. 22	Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials	AQ
May. 15	Intervacc: US progress, while European sales still soft – Q1 review	AQ
May. 15	Emil Billbäck appointed new Chair of the Board of Intervacc	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.23%	-3.08%	+53.96%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.18%	+63.69%	+62.06%	54.15B
INSMED INCORPORATED	+0.72%	-2.19%	+4.36%	+409.54%	23.11B
BIONTECH SE	+0.25%	+0.08%	-17.39%	-15.22%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.76%	+40.14%	-3.59%	20.33B
GENMAB A/S	-0.37%	+0.42%	+37.47%	-31.61%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-2.80%	+37.96%	+600.00%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-12.88%	+168.62%	+289.45%	15B
EXELIXIS, INC.	+1.22%	+0.18%	+25.14%	+182.63%	13.82B
Average	+0.72%	-0.37%	+46.00%	+175.69%	26.51B
Weighted average by Cap.	+1.46%	+1.19%	+46.49%	+138.40%

	2026 *	2027 *
Net sales	17.7M 1.81M 1.59M 1.48M 1.36M 2.55M 175M 2.6M 6.9M 85.57M 6.8M 6.65M 297M	30.05M 3.08M 2.71M 2.51M 2.31M 4.33M 298M 4.41M 11.72M 145M 11.55M 11.3M 504M
Net income	-80.8M -8.27M -7.27M -6.76M -6.21M -11.65M -801M -11.86M -31.52M -391M -31.05M -30.38M -1.36B	-83.65M -8.56M -7.53M -7M -6.43M -12.07M -829M -12.28M -32.63M -404M -32.14M -31.45M -1.4B
Net Debt	-93M -9.52M -8.37M -7.78M -7.15M -13.41M -922M -13.65M -36.27M -450M -35.73M -34.96M -1.56B	-63M -6.45M -5.67M -5.27M -4.85M -9.09M -624M -9.25M -24.57M -305M -24.21M -23.68M -1.06B

Intervacc AB Stock Nasdaq Stockholm

Stocks

Biotechnology & Medical Research

Valuation: Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations: Intervacc AB

Press Releases: Intervacc AB

Managers and Directors: Intervacc AB

Bio Therapeutic Drugs

Financials

Company Profile